#1 Clinical Trials Search in Europe

Afamitresgene Autoleucel

Afamitresgene Autoleucel, also known as ADP-A2M4, is an innovative cell therapy being studied in clinical trials for patients with advanced synovial sarcoma or myxoid/round cell liposarcoma. This article explores the ongoing Phase 2 clinical trial, called SPEARHEAD 1, which aims to evaluate the efficacy and safety of this genetically modified T-cell therapy in patients with these rare and challenging cancers.

Table of Contents

What is Afamitresgene Autoleucel?

Afamitresgene autoleucel, also known as ADP-A2M4 or MAGE-A4c1032T, is an innovative cell therapy being developed to treat certain types of advanced soft tissue sarcomas[1]. It belongs to a class of treatments called advanced therapies, specifically a type of gene therapy that modifies a patient’s own immune cells to fight cancer[1].

Targeted Conditions

Afamitresgene autoleucel is being studied for the treatment of two specific types of soft tissue sarcomas:

  • Advanced Synovial Sarcoma: A rare type of cancer that typically occurs near the joints of the arms, legs, or neck[1].
  • Myxoid/Round Cell Liposarcoma (MRCLS): A type of cancer that develops in fat cells, usually in the limbs or abdomen[1].

These conditions are considered “advanced” when they have spread to other parts of the body (metastatic) or cannot be surgically removed (inoperable)[1].

How It Works

Afamitresgene autoleucel is a personalized treatment that uses the patient’s own T cells, a type of immune cell. Here’s a simplified explanation of how it works:

  1. The patient’s T cells are collected through a process called leukapheresis.
  2. These cells are genetically modified in a laboratory to recognize a specific protein called MAGE-A4, which is found on some cancer cells.
  3. The modified T cells (now called ADP-A2M4) are grown in large numbers.
  4. The patient receives chemotherapy to prepare their body for the treatment.
  5. The modified T cells are infused back into the patient’s body, where they can now recognize and attack cancer cells that express the MAGE-A4 protein[1].

Clinical Trial Overview

A clinical trial called SPEARHEAD 1 is currently evaluating the efficacy and safety of afamitresgene autoleucel. This is a Phase 2 study, which means it’s testing the treatment in a larger group of patients to further assess its effectiveness and safety[1].

The main goal of the study is to measure how well the treatment works by looking at the Overall Response Rate (ORR). This means they’re checking how many patients’ tumors shrink or disappear after treatment[1].

The study is also looking at other important factors such as:

  • How long it takes for patients to respond to the treatment
  • How long the response lasts
  • How long patients live without their cancer getting worse
  • Overall survival rates
  • Safety and side effects of the treatment[1]

Eligibility Criteria

To participate in the clinical trial, patients must meet certain criteria. Some key requirements include:

  • Age between 16 and 75 years
  • Diagnosed with advanced synovial sarcoma or myxoid/round cell liposarcoma
  • Have a specific genetic marker (HLA-A*02) and express the MAGE-A4 protein in their tumor
  • Have previously received certain types of chemotherapy
  • Have measurable disease according to specific criteria
  • Be in relatively good overall health[1]

There are also several factors that might exclude a patient from participating, such as certain medical conditions or previous treatments. A healthcare provider can provide more detailed information about eligibility[1].

Potential Benefits

While the full benefits of afamitresgene autoleucel are still being studied, the treatment has shown promise in early research. Potential benefits may include:

  • Shrinking or eliminating tumors
  • Slowing or stopping the progression of the cancer
  • Improving survival rates for patients with these difficult-to-treat cancers
  • Providing a new treatment option for patients who have not responded to other therapies[1]

Safety Considerations

As with any new treatment, safety is a crucial consideration. The clinical trial is closely monitoring for side effects and adverse events. Some potential risks and safety considerations include:

  • Reactions to the infusion of the modified T cells
  • Potential for the modified T cells to attack healthy tissues
  • Risks associated with the chemotherapy given before the treatment
  • Long-term effects that may not yet be known[1]

It’s important to note that all participants in the clinical trial are closely monitored for any side effects or safety concerns[1].

Aspect Details
Study Name SPEARHEAD 1
Phase Phase 2
Design Single Arm, Open-Label
Treatment Afamitresgene Autoleucel (ADP-A2M4)
Conditions Advanced Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Primary Endpoint Overall Response Rate (ORR) per RECIST v1.1
Key Eligibility Criteria Age 16-75, HLA-A*02 positive, MAGE-A4 expressing tumors
Dosing Single dose, up to 10 billion cells
Administration Intravenous infusion
Follow-up Long-term follow-up required

FAQ

  • What is Afamitresgene Autoleucel? Afamitresgene Autoleucel, also known as ADP-A2M4, is a type of cell therapy that uses a patient's own genetically modified T cells to target cancer cells expressing a specific protein called MAGE-A4.
  • What types of cancer is this treatment being studied for? This treatment is being studied for advanced (metastatic or inoperable) synovial sarcoma and myxoid/round cell liposarcoma, which are rare types of soft tissue cancers.
  • Who is eligible for this clinical trial? Eligible patients must be between 16 and 75 years old, have a confirmed diagnosis of advanced synovial sarcoma or myxoid/round cell liposarcoma, have previously received certain chemotherapy treatments, and have tumors that express the MAGE-A4 protein. They must also have a specific genetic marker called HLA-A*02.
  • How is the treatment administered? Afamitresgene Autoleucel is given as a single dose through intravenous infusion. Before receiving the treatment, patients undergo a process called leukapheresis to collect their T cells, which are then genetically modified and multiplied before being infused back into the patient.
  • What are the main goals of this clinical trial? The main goals of the SPEARHEAD 1 study are to evaluate the effectiveness of Afamitresgene Autoleucel in shrinking tumors (overall response rate), assess its safety and tolerability, and study how long the modified T cells persist in the body (cellular pharmacokinetics).

Ongoing Clinical Trials on Afamitresgene Autoleucel

  • Study of Afamitresgene Autoleucel for Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    France Spain

Glossary

  • Afamitresgene Autoleucel: A type of cell therapy that uses a patient's own genetically modified T cells to target cancer cells expressing the MAGE-A4 protein.
  • Synovial Sarcoma: A rare type of soft tissue cancer that typically occurs near joints in the arms, legs, or other areas of the body.
  • Myxoid/Round Cell Liposarcoma (MRCLS): A rare type of soft tissue cancer that develops from fat cells, typically occurring in the limbs or trunk.
  • MAGE-A4: A protein found on some cancer cells that is targeted by the Afamitresgene Autoleucel therapy.
  • HLA-A*02: A specific genetic marker that patients must have to be eligible for this clinical trial.
  • Leukapheresis: A medical procedure used to collect white blood cells, including T cells, from a patient's blood.
  • T cells: A type of white blood cell that plays a crucial role in the immune system's ability to fight cancer and infections.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • RECIST v1.1: Response Evaluation Criteria in Solid Tumors, a standardized method to measure how well a cancer patient responds to treatment.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References

  1. http://clinicaltrials.eu/trial/study-of-afamitresgene-autoleucel-for-patients-with-advanced-synovial-sarcoma-or-myxoid-round-cell-liposarcoma/